CDK4 and lung carcinoma: In addition, RB1 mutations combined with CDK4/6 deficiency had synthetic viable effect in lung cancer cells, which indicates that the lung cancer patients with RB1 mutations could not be suggested to use Palbociclib (Additional file 1: Fig. S1).